CClinicalTrials.gg
CompletedNCT05945771Updated Jul 14, 2023

Effects of Acute Grape Seed Extract Supplementation on Muscle Metaboreflex in Healthy Young Individuals

An interventional study of Grape seed extract in Dietary Supplementation, sponsored by California Baptist University. Completed at 1 site in United States. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-14.

Sponsored by California Baptist University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled May 2022, registered Jul 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Study summary

The aim of this study was to determine whether grape seed extract (GSE) supplementation could reduce the blood pressure (BP) in response to static exercise and post exercise muscular ischemia (PEMI) in normotensive young adults. In 12 healthy subjects (7 male and 5 female, 24.6±3.4 yr), we compared acute effect of both GSE (600 mg) and placebo (PL: 600 mg) on changes from rest in systolic BP (SBP), diastolic BP (DBP), mean arterial pressure (MAP), heart rate (HR), stroke volume (SV), cardiac output (CO), and total peripheral resistance (TPR) during static exercise (SE) and PEMI. Subjects completed 2 min of SE at 30% of maximal voluntary contraction (MVC) followed by 2 min of PEMI.

02

Conditions studied

  • Dietary Supplementation
03

In context

Lead sponsor

California Baptist University is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy volunteers (SBP \< 120 mmHg, DBP \< 80 mmHg)

Exclusion criteria

Exclusion Criteria:

  • cardiovascular and/or pulmonary disease,
  • musculoskeletal disorders
  • medications that prevent the safe completion of the exercise protocol
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Randomized double blind grape seed extract design

    Grape seed extract

    Dietary Supplement: Grape seed extract

  • Placebo comparator
    Control

    Placebo (starch)

    Dietary Supplement: Grape seed extract

Interventions

  • Dietary supplementGrape seed extract

    Acute effect of dietary supplementation with GSE on hemodynamic responses during static exercise and muscle metaboreflex and during cycling exercise.

06

What researchers measure

Primary outcomes

  1. Systolic blood pressure (mmHg) by sphygmomanometer

    Measured from the brachial artery

    Time frame: 24 hours

  2. Diastolic blood pressure (mmHg) by sphygmomanometer

    Measured from the brachial artery

    Time frame: 24 hours

  3. Mean arterial pressure (mmHg)

    calculated (MAP = (SBP-DBP)/3 + DBP

    Time frame: 24 hours

  4. Heart rate (bpm)

    measured using Physio Flow (non-invasive device)

    Time frame: 24 hours

  5. Stroke volume (ml)

    measured using Physio Flow (non-invasive device)

    Time frame: 24 hours

  6. Cardiac output (l/min)

    calculated: HR (bpm) x SV (ml)

    Time frame: 24 hours

  7. Total peripheral resistance (mmHg/l/min)

    calculated: MAP (mmHg) / CO (l/min)

    Time frame: 24 hours

07

Study locations

1 site
  • California Baptist University
    Riverside, California 92504, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05945771
Lead sponsor
California Baptist University
Responsible party
Sponsor
First posted
Jul 14, 2023
Start date
May 1, 2022
Primary completion
Aug 31, 2022
Completion
Aug 31, 2022
Last update
Jul 14, 2023

Study contacts

Jong-Kyung Kim
principal investigator · California Baptist University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion